Z6尊龙凯时

Abstracts of CARsgen's CT1190B and CT071 Published at ASH 2026 Annual Meeting

Results of CARsgen's Satri-cel for Adjuvant Treatment for Gastric Cancer Presented at ESMO Congress 2026

CARsgen’s CT0596 Administers First Patient Dose in China Phase I Registrational Trial

CARsgen’s CT1190B Administers First Patient Dose in China Phase I Registrational Trial

CARsgen Therapeutics Announces 2026 Interim Results

CARsgen’s CT1190B Received IND Clearance from the NMPA for the Treatment of Patients with Relapsed/Refractory Large B-Cell Lymphoma

CARsgen’s CT0596 Received IND Clearance from the NMPA for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

ESMO Preview | CARsgen to Present Results on Satri-cel at ESMO Congress 2026

CARsgen Announces Approval of Satri-cel, the World’s First CAR T-Cell Therapy Product for Solid Tumors

CARsgen Presents Allogeneic CAR T-cell Products CT0596 and CT1190B at EHA 2026